Dear Healthcare Provider, is a new website that highlights best practices of treating patients with Stage III NSCLC with curative intent through a series of expert panel videos.1
Medical advances in the past 10 years in patients with Stage III NSCLC include:
These advances have helped oncologists refine patient prognosis and treatment for Stage III NSCLC. Curative intent is the goal of treatment in patients with Stage III NSCLC, so it is essential to evaluate each patient on a case-by-case basis.1
Concurrent chemoradiotherapy (cCRT) is the standard of care in treating patients with unresectable Stage III NSCLC.7
Multimodality therapy has been proven to improve outcomes in Stage III NSCLC7,8
Today, cCRT offers patients the potential for treatment with curative intent1
CRT: chemoradiation therapy; NSCLC: non-small cell lung cancer.
References: 1. Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019;26(1):37-42. 2. Farjah F, Flum DR, Ramsey SD, Heagerty PJ, Symons RG, Wood DE. Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol. 2009;4(3):355-363. 3. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193-203. 4. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155. 5. Santana-Davila R, Devisetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015;33(6):567-574. 6. Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C; IASLC Advanced Radiation Technology Committee. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol. 2014;9(11):1598-1608. 7. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1-20.
8. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
View our Privacy Notice.
This product information is intended for US Healthcare Professionals only.
The Information Center at AstraZeneca
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437
©2019 AstraZeneca. AII rights reserved.
US-30911 Last Updated 8/19
AstraZeneca LOGO
This email was sent to because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2019 ION Solutions. All Rights Reserved.